For this reason, in the last decade, various pharmacological inhibitors of the MAPK pathway have been used, directed against mutated BRAF (first generation RAF inhibitors as vemurafenib, encorafenib, dabrafenib, sorafenib) or MEK (binimetinib, cobimetinib, trametinib) in tumor therapy [50,51,52,53]. The gene discussed is MAP2K7; the disease is neoplasm.